SAN FRANCISCO - The disease modifying antirheumatic drug (DMARD) leflunomide (Arava), approved for use in rheumatoid arthritis, may also be an effective therapy for recalcitrant psoriatic arthritis and psoriasis, according to two new studies.
The Weekly Roundup: September 2-6
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Abrocitinib Shows Promise for Prurigo Nodularis
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Exploring Afamelanotide for Vitiligo: Insights into the CUV 105 Phase 3 Clinical Trial
Advanced Laser Eases Acne Scars, Melasma, and Wrinkles